ORIC Pharmaceuticals (NASDAQ:ORIC) Earns Overweight Rating from Cantor Fitzgerald
Cantor Fitzgerald reiterated their overweight rating on shares of ORIC Pharmaceuticals (NASDAQ:ORIC – Free Report) in a research note released on Monday, Benzinga reports. Cantor Fitzgerald also issued estimates for ORIC Pharmaceuticals’ FY2024 earnings at ($1.82) EPS. Several other research analysts have also commented on the company. Wedbush reaffirmed an outperform rating and set a […]
More Stories
Hurricane Watch Issued for Hawaii’s Big Island as Tropical Storm Lala Forms
By Savannah Hulsey Pointer A hurricane watch has been issued for the Big Island of Hawaii as Tropical Storm Lala...
Earnings Are Up Over 50% So Far
By Louis Navellier Through last Friday, 88% of the S&P 500 companies have announced second-quarter results. According to FactSet Earnings...
Trump Orders Navy to Replace Newer Fighter Launch System With Older Steam Catapults
By Timothy Frudd President Donald Trump ordered the Navy on Aug. 13 to return to using steam catapults to launch...
Trade Court Upholds Trump’s Shutdown of $800 De Minimis Duty Exemption
By Matthew Vadum The U.S. Court of International Trade on Aug. 13 upheld the Trump administration’s authority to end the...
Trump Says US Has ‘Total Control’ of Hormuz
By Tom Ozimek President Donald Trump said the United States has “total control” over the Strait of Hormuz, while Energy...
US Annual Inflation Rate Stabilizes in July, Slowing to 3.4 Percent
By Andrew Moran Stabilizing energy prices have helped cool off inflation pressures for the second straight month, new government data...